Therapeutics News and Research

RSS

Hospital for Special Surgery receives grant for new genomics center to study autoimmune diseases

Hospital for Special Surgery in New York City has received a $5.6 million grant from The Tow Foundation to establish the Hospital for Special Surgery Genomics Center.

25 Apr 2013

Nanogels to attack lupus: an interview with Dr Look and Dr Fahmy, Yale University

Nanogels are synthetic particles that can be used for drug delivery. They are approximately 100 nm to 200 nm in diameter, and are made from safe, biocompatible materials: a gel-like interior and a lipid exterior.

24 Apr 2013

Isis Pharmaceuticals starts ISIS-SMNRx Phase 2 study in infants with SMA

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy. SMA is a severe and rare genetic neuromuscular disease characterized by muscle atrophy and weakness and is the most common genetic cause of infant mortality.

24 Apr 2013

CNIO researcher-led consortium to receive MRA grant to advance research in melanoma

A consortium led by the Spanish National Cancer Research Centre's researcher Mar-a S. Soengas −Programme Director of the Centre-s Molecular Pathology Programme and Leader of the CNIO Melanoma Group− has been selected to receive funding from the Melanoma Research Alliance, the most important private international melanoma research foundation, in order to advance research in melanoma; this type of skin tumour represents one of oncology's biggest challenges due to its high incidence and malignancy.

24 Apr 2013

Animal models of Huntington's disease allow better insights into disease's genetics

Scientific progress in Huntington's disease (HD) relies upon the availability of appropriate animal models that enable insights into the disease's genetics and/or pathophysiology.

23 Apr 2013

Scientists discover new agent that removes potentially dangerous cells

Pluripotent stem cells can turn, or differentiate, into any cell type in the body, such as nerve, muscle or bone, but inevitably some of these stem cells fail to differentiate and end up mixed in with their newly differentiated daughter cells.

23 Apr 2013

Phase 1 clinical study of rHIgM22 initiated for treatment of multiple sclerosis

Mayo Clinic and Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in the first clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis.

23 Apr 2013

DecImmune and DSM to develop proprietary antibody therapeutic

DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed an agreement with venture capital funded DecImmune Therapeutics of Cambridge, Massachusetts, USA.

22 Apr 2013

Genetic study defines link between primary sclerosing cholangitis and other autoimmune diseases

Researchers have newly associated nine genetic regions with a rare autoimmune disease of the liver known as primary sclerosing cholangitis (PSC). This brings the total number of genetic regions associated with the disease to 16.

22 Apr 2013

Monoclonal antibody inhibits tumor growth in angiosarcoma and breast cancer

A monoclonal antibody targeting a protein known as SFPR2 has been shown by researchers at the University of North Carolina to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma.

20 Apr 2013

Civitas Therapeutics reports positive results from Phase 2 study of CVT-301 for Parkinson's disease

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS respiratory delivery platform, today announced positive topline results from a Phase 2 clinical trial of CVT-301, an inhaled formulation of levodopa (L-dopa).

20 Apr 2013

SironRX completes enrollment in Cohort 1 to study JVS-100 for wound healing, scar prevention

SironRX Therapeutics Inc., a privately-held, clinical-stage biotechnology company developing novel regenerative therapies to prevent scarring and promote dermal wound repair, is pleased to report that it has completed enrollment of patients in Cohort 1 of its placebo-controlled, randomized, dose escalation double-blind clinical study evaluating the safety and efficacy of JVS-100 to reduce scar formation and improve wound healing in patients receiving surgical sternotomy incisions.

19 Apr 2013

Targacept moving forward with Phase 2b study of TC-5619 for treatment of schizophrenia

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced that it has completed recruitment of patients in the Phase 2b study of TC-5619 as a treatment for negative symptoms and cognitive dysfunction in schizophrenia.

19 Apr 2013

Patient enrollment underway in Phase III trial program to evaluate amikacin inhalation solution

Bayer HealthCare Pharmaceuticals Inc. announced today that patient enrollment is underway in its global Phase III trial program to evaluate the efficacy and safety of adjunctive aerosolized BAY41-6551 versus aerosolized placebo in the treatment of intubated and mechanically ventilated patients with Gram-negative pneumonia receiving standard of care intravenous antibiotics.

19 Apr 2013

New microneedle adhesive is more than 3x stronger than conventional surgical staples

A parasitic worm may hold the answer to keeping skin grafts firmly in place over wounds, according to a new study by researchers at Brigham and Women's Hospital (BWH).

18 Apr 2013

ARMGO Pharma gets $1 million to support ARM210 preclinical work for DMD treatment

ARMGO Pharma and the Muscular Dystrophy Association today announced that $1 Million has been awarded for preclinical work in support of an Investigational New Drug application with the U.S. Food and Drug Administration for ARM210, a novel, orally available, small-molecule Rycal drug that has potential as a treatment for Duchenne muscular dystrophy.

18 Apr 2013

Two abstracts related to Advaxis' ADXS-HPV selected for poster presentation at ASCO meeting

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that two abstracts related to ADXS-HPV (ADXS11-001), the Company's lead clinical stage product candidate, have been selected for poster presentation at the 2013 American Society of Clinical Oncology Annual Meeting in Chicago, IL, from May 31 - June 4, 2013, at the McCormick Place Convention Center.

18 Apr 2013

Mast Therapeutics' data show that MST-188 reduces aggregation of both older and younger RBC

Mast Therapeutics, Inc. today announced that two posters for its lead product candidate, MST-188, were presented at the 7th Annual Sickle Cell Disease Research & Educational Symposium, currently underway in Miami.

18 Apr 2013

Santaris Pharma, Bristol-Myers Squibb partner to develop novel medicines using LNA Drug Platform

Santaris Pharma A/S, a privately held biopharmaceutical company focused on developing medicines targeted to disease-related mRNAs and microRNAs, today announced a worldwide strategic alliance with Bristol-Myers Squibb to discover and develop novel medicines using Santaris Pharma's proprietary Locked Nucleic Acid Drug Platform.

18 Apr 2013

New pre-clinical study suggests novel drug combination therapy for leukemia treatment

A new, pre-clinical study by researchers at Virginia Commonwealth University Massey Cancer Center suggests that a novel drug combination could lead to profound leukemia cell death by disrupting the function of two major pro-survival proteins.

18 Apr 2013

Therapeutics News and Research

Hospital for Special Surgery receives grant for new genomics center to study autoimmune diseases

Nanogels to attack lupus: an interview with Dr Look and Dr Fahmy, Yale University

Isis Pharmaceuticals starts ISIS-SMNRx Phase 2 study in infants with SMA

CNIO researcher-led consortium to receive MRA grant to advance research in melanoma

Animal models of Huntington's disease allow better insights into disease's genetics

Scientists discover new agent that removes potentially dangerous cells

Phase 1 clinical study of rHIgM22 initiated for treatment of multiple sclerosis

DecImmune and DSM to develop proprietary antibody therapeutic

Genetic study defines link between primary sclerosing cholangitis and other autoimmune diseases

Monoclonal antibody inhibits tumor growth in angiosarcoma and breast cancer

Civitas Therapeutics reports positive results from Phase 2 study of CVT-301 for Parkinson's disease

SironRX completes enrollment in Cohort 1 to study JVS-100 for wound healing, scar prevention

Targacept moving forward with Phase 2b study of TC-5619 for treatment of schizophrenia

Patient enrollment underway in Phase III trial program to evaluate amikacin inhalation solution

New microneedle adhesive is more than 3x stronger than conventional surgical staples

ARMGO Pharma gets $1 million to support ARM210 preclinical work for DMD treatment

Two abstracts related to Advaxis' ADXS-HPV selected for poster presentation at ASCO meeting

Mast Therapeutics' data show that MST-188 reduces aggregation of both older and younger RBC

Santaris Pharma, Bristol-Myers Squibb partner to develop novel medicines using LNA Drug Platform

New pre-clinical study suggests novel drug combination therapy for leukemia treatment

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News